33 reports of this reaction
1.7% of all CHLORPROMAZINE HYDROCHLORIDE reports
#9 most reported adverse reaction
SOMNOLENCE is the #9 most commonly reported adverse reaction for CHLORPROMAZINE HYDROCHLORIDE, manufactured by Advagen Pharma Ltd. There are 33 FDA adverse event reports linking CHLORPROMAZINE HYDROCHLORIDE to SOMNOLENCE. This represents approximately 1.7% of all 1,986 adverse event reports for this drug.
Patients taking CHLORPROMAZINE HYDROCHLORIDE who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is a less commonly reported adverse event for CHLORPROMAZINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to somnolence, the following adverse reactions have been reported for CHLORPROMAZINE HYDROCHLORIDE:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 33 FDA reports for CHLORPROMAZINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 1.7% of all adverse event reports for CHLORPROMAZINE HYDROCHLORIDE, making it a notable side effect.
If you experience somnolence while taking CHLORPROMAZINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.